Resurrecting the Autopsy: Benefits and Recommendations
PETER N. NEMETZ, Ph.D., C. MARY BEARD, R.N., M.P.H., DAVID J. BALLARD, M.D., Section of Clinical Epidemiology; JÜRGEN LUDWIG, M.D., Division of Pathology; ERIC G. TANGALOS, M.D., Division of Community Internal Medicine; EMRE KOKMEN, M.D., Department of Neurology; KAREL M. WEIGEL, R.R.A., Department of Administration; PAUL G. BELAU, M.D., Division of Pathology; WILLIAM M. BOURNE, M.D., Department of Ophthalmology; LEONARD T. KURLAND, M.D., Dr.P.H., Section of Clinical Epidemiology
Maintenance of high autopsy rates is associated with specific benefits, especially for clinical practice and for clinical and epidemiologic research. We have compiled and evaluated (on the basis of related costs and benefits) a comprehensive list of recommendations to resurrect the autopsy and reestablish it as a central contributor to medical practice, teaching, and research.
In a companion article, 1 we examined in detail the patterns of autopsy rates for a half century in Olmsted County, Minnesota, and identified the basic medical and socioeconomic variables t h a t may be associated with the autopsy decision. In this article, we discuss the specific benefits asso ciated with maintaining high autopsy rates, especially for clinical practice and for clinical and epidemiologic research at the Mayo Clinic, and we develop generalizable recommendations for reversing the declining rate of autopsies, not only within Olmsted County but also through out the United States.
BENEFITS OF THE AUTOPSY In some respects, it is remarkable t h a t a medical procedure with such a broad and multifaceted range of benefits as the autopsy should have experienced such a pronounced decline. 2 The following list briefly summarizes these benefits with respect to diagnostics, therapeutics, clini cal outcomes, public health, and epidemiology. Autopsies (1) play a critical role in quality control by providing confirmation, clarification, and correction of antemortem clinical diagnoses; (2) aid in the discovery of new or previously unrecognized diseases; (3) provide reassurance and potentially critical information for members of the family of the deceased pertaining to the identification of contagious disease, recognition of genetic disorders, potential organ availabil This investigation was supported in part by Research Grant ity, and peace of mind associated with knowl AR 30582 from the National Institutes of Health, Public edge of the cause of death; (4) contribute toward Health Service. the evaluation of diagnostic technologies and Address reprint requests to Dr. P. N. Nemetz at his current tests; (5) are an indispensable source of primary address: Policy Analysis Division, Faculty of Commerce, or corroborative evidence in cases of sudden, University of British Columbia, Vancouver, BC, Canada suspicious, or unexplained death; (6) play an V6T 1Y8. Mayo Clin Proc 64:1065-1076, 1989
1065
1066 BENEFITS OF AUTOPSY
important role in the evaluation of the efficacy of new drugs and their potential adverse effects; (7) can facilitate the evaluation of the inten tional and unintentional effects of treatment in the newly developing area of genetic engineer ing; (8) furnish valuable information about po tential risks associated with specific therapeutic techniques such as irradiation; (9) can generate information that leads to more effective suppor tive care in cases of cancer and could ultimately prolong patient survival; (10) provide essential information on disease manifestation that can not be provided from living subjects; (11) assist in the evaluation of new surgical techniques; and (12) assist in the assessment of new prostheses in such fields as cardiac and orthopedic surgery. In addition to these general benefits associ ated with the autopsy, two other categories are especially important to the practice of clinical medicine and epidemiology at the Mayo Clinic. Autopsies supply essential tissue for research, teaching, and transplantation. The autopsy plays a central role in providing tissues to such departments as ophthalmology, otorhinolaryngology, and orthopedics. The importance of autopsy tissue at the Mayo Clinic for the period 1982 through 1985 is shown in Table 1. Particu larly significant has been the role of autopsyobtained eyes for corneal transplantation; Table 2 shows the increasing demand for corneal tis sue during the period from 1976 through 1986 at the Mayo Clinic. The trend in this use is such that a shortfall in supply may occur unless remedial measures are undertaken to increase autopsy rates in the near future. Similarly strong sentiments with respect to the importance of the autopsy for teaching, re search, and medical and surgical care were expressed by the Mayo Ad Hoc Committee on Autopsy Review in 1974 and recently reaffirmed by the Mayo Autopsy Task Force Report (May 4, 1987) to the Clinical Practice Committee. Autopsies make substantial contributions to medical and epidemiologic research through studies on incidence and prevalence rates3 and testing of hypotheses for risk factors in the cause of diseases. In addition, autopsies can play a
Mayo Clin Proc, September 1989, Vol 64
Table 1.—Examples of Autopsy Tissue Use for Research, Teaching, and Transplantation at the Mayo Clinic, 1982 Through 1985* Type of tissue Dura Pituitary gland Diaphragm and psoas muscle Middle ears Eyes Trachea Brain Liver Adipose tissue Tendons and nerves Vertebrae
Samples (no.) 2,000 1,812 1,800 1,246 1,060 803 190 123 112 105 100
*Omitted from this list were 30 additional categories of autopsy tissue because the number of samples used dur ing the study period was fewer than 100 in each category.
crucial role in the identification and potential control of new epidemic diseases, one of the foremost examples of which is acquired immu nodeficiency syndrome (AIDS).2 The health sector must compete with other sectors of the economy for scarce resources, and within the health sector itself, important deci sions about the allocation of financial and hu man resources must be made among diseases and between prevention and treatment. Epi demiologic information is an essential prerequi site to the efficient and effective allocation of these resources. Of particular importance with respect to the declining autopsy frequency are studies on wide spread major conditions such as Alzheimer's disease, currently the fourth leading cause of death in the United States, which pose a prob lem in the areas of public health and policy. Estimates of the number of persons affected by this disease range from 1 to 4 million, either institutionalized in nursing homes and hospi tals or cared for at home. At an estimated cost of care in excess of $12 billion per year, this disease represents a considerable financial burden on a nation already beset by rapidly increasing medical costs. 46 As reported by Kokmen and associates,7 "Despite many advances in diagno-
Mayo Clin Proc, September 1989, Vol 64
BENEFITS OF AUTOPSY 1067
Table 2 — C o r n e a l T i s s u e U s e at t h e Mayo Clinic, 1976 T h r o u g h 1986 Donor corneas from: Year
Autopsy
Live donors*
1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986
61 75 104 88 83 116 151 199 195 174 155
1 1 0 0 3 6 9 4 5 4 9
Organ donors
Other eye banks
0 2 0 2 12 4 2 6 2 0 19
14 4 2 0 0 2 0 0 0 0 1
Corneas used in transplantation
At
Else-
Mayo
where
32 45 53 26 59 68 62 53 88 93 86
0 0 0 0 0 4 30 12 16 8 11
Corneas (no.) Total
76 82 106 90 98 128 162 209 202 178 184
Used in transplantation
32 45 53 26 59 72 92 65 104 101 97
*Eye removed because of neoplastic choroidal or orbital disease.
sis, autopsy is still required for diagnosis of Alzheimer's disease." Organs, organ systems, and tissues obtained at autopsy are fundamental resources for any research that considers the influence of normal aging and development on the anatomic and physiologic features of human systems. De tailed quantitative studies of "the normal" at various ages and stages of development are crucial for the understanding of perturbations caused by disease processes. Careful harvesting of tissues, their adequate preservation in con junction with detailed and appropriate clinical descriptions, and analysis of the source of tis sues are important for future generations of researchers who may be addressing questions that are not being considered at the present time. If autopsy material is not available, re search on aging or the pathogenesis of chronic diseases will be impossible. A good example is the study of cholinergic systems and their pa thologic derangements in Alzheimer's disease.8 A lack of corroborative autopsy studies can lead to difficulties with the publication of results of medical research and thereby impede the timely dissemination and exchange of impor tant research findings. Perhaps the most important contribution of autopsy studies to epidemiology at the Mayo
Clinic has been made through the Rochester Epidemiology Program Project (REPP). Estab lished in 1966 with funding from the National Institutes of Health, the REPP uses the Mayo diagnostic and surgical indexes and recordslinkage system 920 to produce population-based epidemiologic studies. The exceptional quality of this data base is attributable to its virtually complete longitudinal coverage of a geographi cally defined population since the beginning of the century. In the 23 years since its inception, Mayo physicians and visiting scholars associ ated with the REPP have produced almost 500 publications on a diverse range of subjects. The work has been focused on neurology, cardiovas cular diseases, and cancer but also includes at least 16 other general medical categories. The records-linkage system facilitates the genera tion of not only highly accurate incidence and prevalence rates but also studies on risk factors and cross-disease hypothesis testing. In numerous cases, the REPP has been able to generate the first population-based incidence rates for specific diseases, especially within the field of neuroepidemiology. This and similar achievements in the study of incidence of dis eases have often been made possible by the high level of autopsy confirmation at the Mayo Clinic. An integral part of this system are the tissue
1068 BENEFITS OF AUTOPSY
Mayo Clin Proc, September 1989, Vol 64
storage facilities, which allow retrieval and diagnostic verification of cases for a period of several decades. The specific contribution of the autopsy to Mayo epidemiologic research is manifested in at least three ways: (1) by allowing a high level of case verification alone or in combination with
biopsy results; (2) by enhancing the comprehen siveness of case ascertainment through initial diagnosis of diseases or medical conditions (for example, such autopsy-related diagnoses account for 40% of all primary benign and malignant brain tumors and 45% of all cases of pheochromocytoma); and (3) by facilitating the testing of
Table 3.—Partial L i s t i n g of Autopsy-Assisted R e s e a r c h at t h e Mayo Clinic, b y T y p e of S t u d y Reference
Subject Case verification in studies of incidence, prevalence, and Amyotrophic lateral sclerosis Angina pectoris Bronchogenic carcinoma Dementia Hemispheric and brain-stem infarction Infective endocarditis Leukemia Malignant lymphoma Multiple myeloma Myocardial infarction Parkinsonism Stroke Sudden infant death syndrome Sudden unexpected cardiac death Enhancement of comprehensiveness of case ascertainment through initial diagnosis of condition at autopsy Colorectal cancer Encephalitis Intracranial neoplasms Occult carcinomas of the thyroid Pheochromocytoma Polycystic kidney disease Primary brain tumors Primary intraspinal neoplasms Renal cell carcinoma Hypothesis testing for disease interrelationship Cancer and seizure disorders Cancer after herpes zoster Cholelithiasis and carcinoma of the colon Colorectal polyps (>1 cm in diameter) and subsequent carcinoma Diabetes and coronary artery disease Diabetes mellitus and lymphoma Diabetes mellitus and subsequent cancer Gastric carcinoma after partial gastrectomy Hashimoto's thyroiditis and breast cancer Herpes zoster and diabetes mellitus Herpes zoster and multiple sclerosis Pernicious anemia and gastric carcinoma Rheumatoid arthritis and subsequent cancer Treatment for small colorectal polyps and subsequent carcinoma
survival
Autopsy 56 41 60 54 38 43 74 58 61 49 86 48 50 86 100 87 Initial diagnosis at autopsy 12 2 35 6 45 29 40 38 37
34 35 36 37 32 38 39 40 41 42 36 43 44 45 46 47
48 49 50 51 52 53 54 55 56 26 57,58 59 60 61 62,63 64 65,66 67 68 69 70 71 72
Mayo Clin Proc, September 1989, Vol 64
hypotheses about interrelationships among dis eases and medical conditions. Autopsy verification has played a critical role in studies on lupus erythematosus, 21 neural tu mors,22 multiple myeloma,23 carcinoma of the stomach,24 bronchogenic carcinoma,25 primary brain tumors, 26 malignant lymphoma,27 infec tions of the central nervous system,28 pancreati tis, 29 diabetes,30 sudden unexpected death in children and adolescents,31 and Alzheimer's dis ease,32·33 in addition to the diseases described in Table 3.
BENEFITS OF AUTOPSY 1069
sive remedial strategy must ultimately be driven by an understanding and commitment from the medical community, the government, and the general public. In an era when rapidly increasing costs of medical care threaten to jeopardize government budgeting processes and the availability of an acceptable minimal standard of care for all Americans, when senior citizens even more dependent on public support and with a growing burden of health needs constitute an increasing proportion of our population, and when new and major challenges to medical care and epidemiologic research are posed by such threats as Alz CONCLUSIONS AND heimer's disease and AIDS, the autopsy remains RECOMMENDATIONS A wide range of medical, legal, social, and eco one of the central pillars of modern medicine. nomic causes underlies the decline in autopsy rates; thus, any effort at amelioration must have ACKNOWLEDGMENT an equally broad focus.1 A synthesis of the We express our gratitude to the following per numerous and diverse recommendations for sons, who provided valuable assistance in the increasing autopsy rates, as suggested in the preparation of this article: Marilyn Billings, recent medical literature, is presented in Table Death Registrar, Olmsted County, Minnesota; 4. This tabulated information includes a brief Chu-Pin Chu, Dianne M. Shimek, James R. assessment of each of these proposals in a quali Wentz, and William F. Taylor, Ph.D., Depart tative cost-benefit framework. A three-point ment of Health Sciences Research; Patricia L. scale (low, medium, or high) is used to evaluate Kasey and John R. Ostrander, Division of Pa the "costs" of these recommendations, including thology; and Sarah Lehman, Vancouver, British their direct financial burden and the difficulty of Columbia, Canada. their implementation. The "benefits" are as sessed in terms of the magnitude of their antici pated effect and the time scale for their imple REFERENCES 1. Nemetz PN, Ballard DJ, Beard CM, Ludwig J, Tanmentation. Because the evaluation of the pro galos EG, Kokmen E, Weigel KM, Belau PG, Bourne posed policy measures in Table 4 must be largely WM, Kurland LT: An anatomy of the autopsy, subjective, the general criteria used in formulat Olmsted County, 1935 through 1985. Mayo Clin Proc 64:1055-1064, 1989 ing this assessment are outlined in Table 5. 2. Nemetz PN, Ludwig J, Kurland LT: Assessing the In total or in part, these multifaceted recom autopsy. Am J Pathol 128:362-379, 1987 mendations can provide a comprehensive "pro 3. McFarlane MJ, Feinstein AR, Wells CK, Chan CK: gram for the nation" to resurrect the autopsy The 'epidemioloic necropsy': unexpected detections, demographic selections, and changing rates of lung and reestablish it as a central contributor to cancer. JAMA 258:331-338, 1987 medical research, teaching, and practice. As 4. Schoenberg BS, Okazaki H, Kokmen E: Reduced indicated, some of these recommendations could survival in patients with dementia: a population study. Trans Am Neurol Assoc 106:306-308, 1981 have a direct, immediate, and salutary influence 5. Terry RD, Katzman R: Senile dementia of the Alz on the rate of autopsies; others, in contrast, by heimer type. Ann Neurol 14:497-506, 1983 raising the visibility of the autopsy and commu 6. Specific protein found in brains of Alzheimer's dis ease patients. The New York Times, Apr 25, 1986, nicating its value more clearly to both medical pl5 and nonmedical communities, would lead to a 7. Kokmen E, Offord KP, Okazaki H: A clinical and more favorable long-term acceptance of this autopsy study of dementia in Olmsted County, Min procedure. The implementation of a comprehen nesota, 1980-1981. Neurology 37:426-430, 1987
1070 BENEFITS OF AUTOPSY
Mayo Clin Proc, September 1989, Vol 64
Table 4.—Partial Listing of Recommendations for Increasing Autopsy Rates
Target General public
General focus Public education
Autopsy consent
Autopsy feedback
Medical community
Medical research, including epidemi ology
Specific recommendation Incorporate discussion of autopsy benefits into health letters from private institutions (for example, "Mayo Clinic Health Letter," "Harvard Medical School Health Letter") Use government brochures sent to recipients of Medicare, Medicaid, and other healthrelated programs to discuss benefits of the autopsy Incorporate autopsy benefit information in hospital bro chures to patients Provide information on the value of the autopsy to journals direct ed toward the aged and retired Provide estate planners with brochures on the autopsy Tie autopsy requests more closely to legislation for organ donation Reverse onus of consent, so that an autopsy is permitted unless family objects Require autopsy request as part of hospital admission procedure Give relatives the right to require an autopsy (as is current prac tice in Finland) Use professional liaison, such as a specially trained nurse, social worker, or physician's assis tant, to make coordinated con tact with bereaved families Schedule postautopsy confer ences with surviving family members Provide guidelines to physicians for talking to bereaved families Require a minimal autopsy rate in grant funding Develop an automated encoding and retrieval system for autopsy data for local or national use Develop a national computer autopsy data base to increase the dissemination and value of autopsy data Formulate national policies to modernize and promote use of the autopsy Promote use of updated autopsy protocols for medical research, particularly in cancer and in cardiovascular, occupational, and infectious diseases
Reference
Costs Difficulty Direct of implemencosts tation
Benefits Magnitude of effect
Time until effect
Low
Low
Low
Longterm
Low
Low
Low
Longterm
73
Low
Low
Low
Longterm
74
Low
Low
Low
Longterm
74
Low
Medium
Low
Longterm
Low
High
Medium
Longterm
75,76
Low
High
High
Shortterm
77
Low
Medium
Medium
78
Low
High
Medium
Shortterm Shortterm
74,75, 79
Medium
Medium
Medium
Longterm
75,76, 80,81
Low
Medium
Low
Longterm
82
Low
Low
Medium
Longterm
83*
Low
High
High
Shortterm Longterm
Medium
84
High
Medium
85-87
High
High
85,86
Medium
Medium
85
Medium
Medium
Medium
Longterm
Medium
Longterm
Medium
Longterm
Mayo Clin Proc, S e p t e m b e r 1989, Vol 64
BENEFITS OF AUTOPSY
1071
Table 4.—Continued Costs Target
General focus
Medical community (cont)
Medical student education
Medical practice
Autopsy economics
Specific recommendation
Reference
Direct costs
Benefits
Difficulty of implemen tation
Magnitude of effect
Time until effect
Include demographic data sets in autopsy reports Introduce random selection of autopsy in order to reduce bias in quality assessment and epidemiologic findings
86
Low
Medium
Low
88,89
Medium
Medium
Medium
Increase the emphasis in the curriculum on the benefits of the autopsy Reintroduce autopsy require ments into undergraduate and graduate medical programs Reintroduce autopsy percentage criteria as part of medical school accreditation
75,79
Low
Medium
Medium
Longterm
85,86, 90,91
Medium
High
Medium
Longterm
85t
Low
High
Medium
Longterm
76,85
Low
Medium
Medium
Shortterm
92
Low
Low
Low
Longterm
93
Low
Medium
Low
Longterm
t
High
High
High
Shortterm
85,86t
Medium
High
Medium
Longterm
91§
Medium
High
High
Shortterm
77,85, 86,94, 95
High
High
High
Shortterm
96,97
Medium
High
Medium
Longterm
88,98
Medium
Medium
High
Shortterm
99
High
High
Medium
Longterm
Reestablish a minimal autopsy percentage by the Joint Commission for Accreditation of Hospitals Emphasize use of h u m a n tissue for research and transplanta tion Forward appropriate autopsy findings to a committee for potential revision of patient care practices Seek a specific diagnosisrelated group (DRG) descriptor for the autopsy Link the autopsy to the riskquality assurance role of the DRG system Negotiate on a hospital-byhospital basis direct cash incentives for pathologists to conduct autopsies Recognize the autopsy as a phy sician service, billable on a "reasonable charge basis" under part B of Medicare, or adopt other specific methods of reimbursement Encourage medical institutions to self-finance autopsies to lower risk of malpractice cases and awards (alterna tively, hospitals could propose sharing these costs with insurance carriers on grounds of mutual benefit) Encourage insurance industry to provide discount on liability premiums to clinicians who obtain high autopsy rates on deceased patients Include the autopsy as a cost of research and education
Longterm Longterm
1072 BENEFITS OF AUTOPSY
Mayo Clin Proc, S e p t e m b e r 1989, Vol 64
Table 4.—Continued
Target
General focus
Medical com munity (cont)
Physician education
Nonmedical support person nel and organ izations
Nursing homes
Specific recommendation
Reference
Costs Difficulty Direct of implemencosts tation
Benefits Magnitude of effect
Time until effect
Reduce costs in various ways— for example, do problemoriented autopsies in selected cases, obtain frozen sections when they will suffice or pend ing a decision about what is to be done with retained material, do regional autopsies in the case of small hospitals, or use the pathology assistant as a professional prosector
100
Low
Low
Medium
Longterm
Institute special programs to help physicians counsel families Increase flow of information within hospitals and clinics on the value of autopsies (for example, use of clinical abstract forms, weekly autopsy conferences, expedi tious autopsy reporting, anno tated histograms of diagnostic results for effective dissemina tion of information, or consulta tive partial autopsy reviews) Establish international "autopsy club" as forum for dissemina tion of information Survey academics in medical community to determine their perception of autopsy programs G r a n t credit for continuing education from attendance at autopsies Alter training of pathologists in the direction of more specialization in anatomic pathology and further subspecialization in various organ systems, as in internal med icine, to provide more infor mation from the autopsy to clinicians and surgeons
86
Medium
Medium
Low
Longterm
85,86*
Medium
High
Medium
Longterm
86
Low
Low
Low
Longterm
86
Medium
Low
Low
Longterm
101
Low
Medium
Low
Longterm
102
Medium
High
Medium
Longterm
Low
High
Medium
Longterm
Low
High
High
Longterm
Medium
High
Low
Longterm
Make autopsy counseling a condition of state licensing or of federal reimburse ment programs Make a minimal level of autopsies a condition of federal reimbursement programs Promote the affiliation of nursing homes with academic organizations to create enhanced opportunities for teaching and research
103
MayoClin Proc, September 1989, Vol 64
BENEFITS OF AUTOPSY 1073
Table 4.—Continued
Target
General focus
Nonmedical... (cont)
Insurance industry
Others
Other organ izations
Govern ment Employers and unions
Specific recommendation Link a minimal autopsy rate to coverage for institutions or individuals on the grounds that the additional information provided by the autopsy can lead to fewer malpractice cases and awards and ultimately to lower insurance costs Produce videotapes for social workers, clergy, and hospital administrators to demonstrate the value of the autopsy Sponsor joint meetings between pathology societies and appro priate agencies to enhance educa tion on the autopsy Encourage private sector employ ers and unions to include autopsies in their fringe benefit programs
Reference
Costs Difficulty Direct of implemen costs tation
Benefits Magnitude of effect
Time until effect
96,97, 104
Low
High
High
Longterm
93
Medium
Medium
Low
Longterm
83
Low
Medium
Low
Longterm
105
High
High
Medium
Longterm
*Cartwright H: Personal communication (Oct. 31, 1986). tChavigny K: Personal communication (Nov. 3, 1986). tSinton E: Personal communication (Nov. 10, 1986). §Lundberg G: Personal communication (Nov. 7, 1986).
Table 5.—Evaluative Criteria U s e d i n A s s e s s i n g P o l i c y R e c o m m e n d a t i o n s To I n c r e a s e t h e A u t o p s y R a t e Rating
Direct costs
High
Substantial expenditures of public or private funds (or both) seem to be required
Medium
Only a modest expenditure of funds seems to be required
Low
No cost or only token expenditures seem to be involved
Difficulty in implementation Likely to involve use of substantial nonmonetary resources (for example, specially trained personnel) or to encounter consider able or insurmountable institutional resistance Likely to involve only modest use of nonmonetary resources (for example, specially trained personnel) or to encounter some institutional resistance t h a t can be overcome with reasonable effort Likely to involve few nonmonetary resources (for example, specially trained personnel) and little or no institu tional resistance
Magnitude of effect
Time until effect
Result is likely to increase autopsy rates substantially
An immediate effect on autopsy rates is expected
Shortterm
Result is likely to have a mod est, although noticeable, effect on autopsy rates
Not applicable
Not applicable
Result is likely to have minimal or no effect on autopsy rates
A delayed effect (for example, several years) on autopsy rates is expected
Longterm
Time scale
1074 BENEFITS OF AUTOPSY
8.
9. 10.
11.
12.
13. 14.
15.
16.
17.
18. 19.
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basilis. Ann Neurol 10:122-126, 1981 Kurland LT, Molgaard CA: The patient record in epidemiology. Sei Am 245:54-63, October 1981 Kurland LT: The role of the Mayo Clinic in the epidemiology of neurologic and other diseases in Olmsted County, Minnesota, and results of initial long-term trend studies. Clin Neurol (Japan) 10:817, 1970 Kurland LT, Elveback LR, Nobrega FT: Popula tion studies in Rochester and Olmsted County, Minnesota, 1900-1968. In The Community as an Epidemiologie Laboratory: A Casebook of Commu nity Studies. Edited by II Kessler, ML Levin. Baltimore, Johns Hopkins Press, 1970, pp 47-70 Kurland LT, Elveback LR, Nobrega FT: Mayo Clinic records linkage system in the RochesterOlmsted epidemiology program project. In Uses of Epidemiology in Planning Health Services. Edited by AM Davies. Belgrade, Yugoslavia, Savremena Administracija, 1973, pp 164-176 Kurland LT, Brian DD: Contributions to neurol ogy from records linkage in Olmsted County, Minnesota. Adv Neurol 19:93-105, 1978 Kurland LT, Annegers J F , O'Fallon W: Utilization of Mayo Clinic records for population-based longterm evaluations of drug exposure. In Computer Aid to Drug Therapy and to Drug Monitoring. Edited by H Ducrot, M Goldberg, R Hoigne, P Middleton. Amsterdam, North Holland Publish ing Company, 1978, pp 69-76 Kurland LT, Annegers J F , Lutz TD: The Mayo Clinic patient data base with emphasis on epi demiology and long-term effects of drugs in the population of Olmsted County, Minnesota. Pro ceedings of the Second Annual Conference, World Association for Medical Informatics, Symposium on Medical Informatics. Versailles, France, March 19 to 22, 1979 Kurland LT: The contribution of the Mayo Clinic centralised diagnostic index to neuroepidemiology in the United States. In Clinical Neuroepidemiol ogy. Edited by FC Rose. Tunbridge Wells, Eng land, Pitman Medical, 1980, pp 37-46 O'Fallon WM, Beard CM, Weigel KM, Kurland LT: The clinical record as an epidemiological data source: the Rochester Project experience. In Pro ceedings of the Fourteenth Hawaii International Conference on System Sciences. Vol 2, Section 1. Edited by B Shriver, TM Walker, RR Grams, RH Sprague Jr. Hollywood, California, Western Peri odicals Company, 1981, pp 123-143 Kurland LT, Molgaard CA, Schoenberg BS: Mayo Clinic records-linkage: contributions to neuroepi demiology. Neuroepidemiology 1:102-114, 1982 Kurland LT, Molgaard CA, Weigel KM: The mini m u m basic data set and epidemiologic research: the Mayo Clinic experience. In Hospital Statistics in Europe. Edited by PM Lambert, F H Roger.
Mayo Clin Proc, September 1989, Vol 64
20.
21.
22.
23.
24.
25. 26. 27.
28.
29.
30. 31. 32.
33.
34.
Brussels, North Holland Publishing Company, 1982, pp 24-41 Kurland LT: The Rochester Epidemiology Pro gram Project. In Current Topics in Rheumatology: Epidemiology of the Rheumatic Diseases. Edited by RC Lawrence, LE Shulman. New York, Gower Medical Publishing, 1984, pp 359-363 Nobrega FT, Ferguson RH, Kurland LT, Hargraves MM: Lupus erythematosus in Rochester, Minnesota, 1950-1965: a preliminary study. Excerpta Medica International Congress Series No. 148, 1968, pp 259-266 Kurland LT: Geography of neural tumors. In Pathology oftheNervous System. Vol3. Editedby J Minckler. New York, McGraw-Hill Book Com pany, 1972, pp 2803-2808 Linos A, Kyle RA, O'Fallon WM, Kurland LT: Incidence and secular trend of multiple myeloma in Olmsted County, Minnesota: 1965-77. J Natl Cancer Inst 66:17-20, 1981 Nobrega FT, Sedlack JD, Sedlack RE, Dockerty MB, Ilstrup DM, Kurland LT: A decline in carci noma ofthe stomach: a diagnostic artifact? Mayo Clin Proc 58:255-260, 1983 Beard CM, Annegers J F , Woolner LB, Kurland LT: Bronchogenic carcinoma in Olmsted County, 19351979. Cancer 55:2026-2030, 1985 Shirts SB, Annegers J F , Hauser WA, Kurland LT: Cancer incidence in a cohort of patients with sei zure disorders. J Natl Cancer Inst 77:83-87,1986 Linos A, Beard CM, Banks PM, Kurland LT: Malignant lymphoma in Olmsted County, Minne sota, 1970 through 1977. Mayo Clin Proc 61:706713, 1986 Nicolosi A, Hauser WA, Beghi E, Kurland LT: Epidemiology of central nervous system infections in Olmsted County, Minnesota, 1950-1981. J In fect Dis 154:399-408, 1986 O'Sullivan JN, Nobrega FT, Morlock CG, Brown AL Jr, Bartholomew LG: Acute and chronic pan creatitis in Rochester, Minnesota, 1940 to 1969. Gastroenterology 62:373-379, 1972 Ochi JW, Melton LJ III, Palumbo PJ, Chu C-P: A population-based study of diabetes mortality. Diabetes Care 8:224-229, 1985 Driscoll DJ, Edwards WD: Sudden unexpected death in children and adolescents. J Am Coll Cardiol 5 (Suppl):118B-121B, 1985 SchoenbergBS,KokmenE,OkazakiH: Alzheimer's disease and other dementing illnesses in a defined United States population: incidence rates and clinical features. Ann Neurol 22:724-729, 1987 Kokmen E, Chandra V, Schoenberg BS: Trends in incidence of dementing illness in Rochester, Min nesota, in three quinquennial periods, 1960-1974. Neurology 38:975-980, 1988 Kurland LT, Choi NW, Sayre GP: Implications of incidence and geographic patterns on the classifi cation of amyotrophic lateral sclerosis. In Motor Neuron Diseases: Research on Amyotrophic Lat eral Sclerosis and Related Disorders. Edited by
BENEFITS OF AUTOPSY 1075
Mayo Clin Proc, September 1989, Vol 64
35.
36.
37.
38.
39.
40.
41.
42. 43.
44. 45.
46.
47.
48.
FH Norris Jr, LT Kurland. New York, Grune & Stratton, 1969, pp 28-50 Yoshida S, Mulder DW, Kurland LT, Chu C-P, Okazaki H: Follow-up study on amyotrophic lat eral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 5:61-70, 1986 Elveback LR: Coronary heart disease in Roches ter, Minn., 1950-1975: incidence and survivorship. In Proceedings of the Conference on the Decline in Coronary Heart Disease Mortality (NIH Publica tion No. 79-1610). Edited by R J Havlik, M Feinleib. Washington, DC, US Department of Health, Education, and Welfare, Public Health Service, 1979, pp 116-123 Byrd RB, Nobrega FT, Divertie MB, Carr DT, Woolner LB, Kurland LT: The 30-year trend of bronchogenic carcinoma in Olmsted County, Min nesota, 1935-1964. J Chronic Dis 24:9-18, 1971 Turney TM, Garraway WM, Whisnant J P : The natural history of hemispheric and brainstem in farction in Rochester, Minnesota. Stroke 15:790794, 1984 Griffin MR, Wilson WR, Edwards WD, O'Fallon WM, Kurland LT: Infective endocarditis: Olmsted County, Minnesota, 1950 through 1981. JAMA 254:1199-1202, 1985 Kyle RA, Nobrega FT, Kurland LT, Elveback LR: The 30-year trend of leukemia in Olmsted County, Minnesota, 1935 through 1964. Mayo Clin Proc 43:342-353, 1968 Nobrega FT, Kyle RA, Harrison EG J r : Malignant lymphoma including Hodgkin's disease occurring in the vicinity of a large medical center (Olmsted County,Minn., 1945through 1969). Cancer 31:295302, 1973 Kyle RA, Nobrega FT, Kurland LT: Multiple myeloma in Olmsted County, Minnesota, 19451964. Blood 33:739-745, 1969 Nobrega FT, Glattre E, Kurland LT, Okazaki H: Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. ExcerptaMedica International Congress Series No. 175, 1969, pp 474-485 Whisnant J P , Fitzgibbons J P , Kurland LT, Sayre GP: Natural history of stroke in Rochester, Minne sota, 1945 through 1954. Stroke 2:11-22, 1971 Fitzgibbons J P Jr, Nobrega FT, Ludwig J, Kurland LT, Harris LE: Sudden, unexpected, and unex plained death in infants. Pediatrics 43:980-988, 1969 Ludwig J, Fitzgibbons J P , Nobrega FT: Sudden unexpected unexplained death in infants: a com parative clinicopathologic study. Virchow Arch [ P a t h A n a t ] 346:287-301,1969 Beard CM, Griffin MR, Offord KP, Edwards WD: Risk factors for sudden unexpected cardiac death in young women in Rochester, Minnesota, 1960 through 1974. Mayo Clin Proc 61:186-191, 1986 Lanier AP, Wychulis AR, Dockerty MB, Elveback LR, Beahrs OH, Kurland LT: Colorectal cancer in
49.
50. 51.
52.
53.
54.
55. 56.
57.
58. 59. 60. 61.
62. 63.
Rochester, Minnesota, 1940-1969. Cancer 31:606615, 1973 Beghi E, Nicolosi A, Kurland LT, Mulder DW, Hauser WA, Shuster L: Encephalitis and aseptic meningitis, Olmsted County, Minnesota, 19501981. I. Epidemiology. A n n N e u r o l 16:283-294, 1984 Annegers J F , Schoenberg BS, Okazaki H, Kurland LT: Epidemiologie study of primary intracranial neoplasms. Arch Neurol 38:217-219, 1981 Sampson RJ, Woolner LB, Bahn RC, Kurland LT: Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with t h a t in Hiroshima and Nagasaki, J a p a n . Cancer 34:2072-2076, 1974 Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT: Occurrence of pheochromocytoma in Roches ter, Minnesota, 1950 through 1979. Mayo Clin Proc 58:802-804, 1983 Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT: Epidemiology of adult polycystic kidney disease, Olmsted County, Min nesota: 1935-1980. Am J Kidney Dis 2:630-639, 1983 Schoenberg BS, Christine BW, Whisnant J P : The resolution of discrepancies in the reported inci dence of primary brain tumors. Neurology 28:817823, 1978 Sasanelli F, Beghi E, Kurland LT: Primary intraspinal neoplasms in Rochester, Minnesota, 19351981. Neuroepidemiology 2:156-163, 1983 Resseguie LJ, Nobrega FT, Farrow GM, Timmons JW J r , Worobec TG: Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 19501974, with special reference to clinical and patho logic features. Mayo Clin Proc 53:503-510, 1978 Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO: Risk of cancer after herpes zoster: a population-based study. N E n g l J M e d 307:393397, 1982 Riegelman R: Cancer and herpes zoster (letter to the editor). N Engl J Med 307:1706-1707, 1982 Linos DA, O'Fallon WM, Thistle JL, Kurland LT: Cholelithiasis and carcinoma of the colon. Cancer 50:1015-1019, 1982 Lotfi AM, Spencer RJ, Ilstrup DM, Melton LJ III: Colorectal polyps and the risk of subsequent carci noma. Mayo Clin Proc 61:337-343, 1986 Palumbo PJ, Elveback LR, Connolly DC: Coronary h e a r t disease and congestive h e a r t failure in the diabetic: epidemiological aspects; the Rochester Diabetes Project. In Clinical Cardiology and Dia betes. Vol 1. Edited by RC Scott. Mount Kisco, New York, F u t u r a Publishing Company, 1981, pp 13-28 Ragozzino MW, Melton LJ III, Palumbo PJ, Chu CP: Risk of lymphoma in individuals with diabetes mellitus. J Chronic Dis 36:363-365, 1983 Severson RK: Association between diabetes and subsequent lymphoma (letter to the editor). J Chronic Dis 37:313-314, 1984
1076 BENEFITS OF AUTOPSY
64.
65.
66.
67. 68. 69.
70.
71.
72.
73. 74. 75. 76. 77. 78. 79.
80. 81. 82.
Ragozzino M, Melton LJ III, Chu C-P, Palumbo P J : Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13-19, 1982 Schäfer LW, Larson DE, Melton L J III, Higgins JA, Ilstrup DM: The risk of gastric carcinoma after surgical treatment for benign ulcer disease: a population-based study in Olmsted County, Min nesota. N E n g l J M e d 309:1210-1213,1983 Del Junco DJ, Del Junco GW J r ; Logan RFA, Langman MJS: Gastric cancer after gastric opera tions (letters to the editor). N E n g l J M e d 310:11921193, 1984 MaruchiN.Annegers J F , Kurland LT: Hashimoto's thyroiditis and breast cancer. Mayo Clin Proc 51:263-265, 1976 Ragozzino MW, Melton LJ, Kurland LT: Herpes zoster and diabetes mellitus: an epidemiological investigation. J Chronic Dis 36:501-505, 1983 Ragozzino MW, Kurland LT: Epidemiologie inves tigation of the association between herpes zoster and multiple sclerosis. Neurology 33:648-649, 1983 Schäfer LW, Larson DE, Melton LJ III, Higgins JA, Zinsmeister AR: Risk of development of gas tric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minne sota. Mayo Clin Proc 60:444-448, 1985 Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E: Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 78 (Suppl 1Α):50-55, 1985 Spencer RJ, Melton LJ III, Ready RL, Ilstrup DM: Treatment of small colorectal polyps: a popula tion-based study of the risk of subsequent carci noma. Mayo Clin Proc 59:305-310, 1984 Geller SA: Autopsy. Sei Am 248:124-129; 132; 135-136, March 1983 Brown HG: Lay perceptions of autopsy. Arch Pathol Lab Med 108:446-448, 1984 McPhee SJ, Bottles K: Autopsy: moribund art or vital science? Am J Med 78:107-113, 1985 McPhee SJ, Bottles K, Lo B, Saika G, Crommie D: To redeem them from death: reactions of family members to autopsy. Am J Med 80:665-671,1986 Reichert CM, Kelly VL: Prognosis for the autopsy. Health Aff (Millwood) 4:82-92, Summer 1985 Svendsen E, Hill RB: Autopsy legislation and practice in various countries. Arch Pathol Lab Med 111:846-850,1987 Beneke JA, Suvalsky SD, McManus BM: The autopsy in medical science and clinical practice: what are we doing in Nebraska? Nebr Med J 71:222-229, 1986 Reynolds RC: Autopsies—benefits to the family. Am J Clin Pathol 69 (Suppl 2):220-222, 1978 Valdes-Dapena M: The postautopsy conference with families. Arch Pathol Lab Med 108:497-498, 1984 Hirsch CS: Talking to the family after an autopsy. Arch Pathol Lab Med 108:513-514, 1984
Mayo Clin Proc, September 1989, Vol 64
83. 84. 85. 86. 87.
88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105.
Hill RB Jr: Conference recommendations. Arch Pathol Lab Med 108:512, 1984 Smith C: The autopsy diagnosis (editorial). Hum Pathol 17:645-647, 1986 Council on Scientific Affairs: Autopsy: a compre hensive review of current issues. JAMA 258:364369, 1987 Anderson RE: Autopsy-related initiatives in the United States: current status and suggestions for the future. H u m Pathol 18:977-979, 1987 Carter JR, Nash NP, Cechner RL, Platt RD: Pro posal for a national autopsy data bank: a potential major contribution of pathologists to the health care ofthe nation. Am J Clin Pathol 76 (Suppl):597617, 1981 Lundberg GD: Now is the time to emphasize the autopsy in quality assurance (editorial). JAMA 260:3488, 1988 F r i e d e n d HHR: Reflections on the postmortem audit. JAMA 260:3461-3465, 1988 Travers H: Mortui vivos docent: the dead teach the living. Kans Med 87:329-333, 1986 Geller SA: To see or not to see: the status of the autopsy at the Mount Sinai Medical Center. Mt Sinai J Med (NY) 46:33-38, 1979 KingDW: Potential of the autopsy. Arch Pathol Lab Med 108:439-443, 1984 Smith RD, Zumwalt RE: One department's expe rience with increasing the autopsy rate. Arch Pathol Lab Med 108:455-457, 1984 Dorsey DB: A perspective on the autopsy. Am J Clin Pathol 69 (Suppl):217-219, 1978 Pontius EE: Financing mechanisms for autopsy. Am J Clin Pathol 69 (Suppl):245-247, 1978 Valaske MJ: Loss control/risk management: a survey of the contribution of autopsy examination. Arch Pathol Lab Med 108:462-468, 1984 Clark MA: The value of the hospital autopsy: is it worth the cost? Am J Forensic Med Pathol 2:231237, 1981 Friederici HHR: Turning autopsy liabilities into assets (letter to the editor). JAMA 250:1165,1983 Shapiro MJ: Reimbursement for autopsies: a personal view. Arch Pathol Lab Med 108:473-474, 1984 Yesner R, Robinson MJ, Goldman L, Reichert CM, Engel L: A symposium on the autopsy. Pathol Annu 20 (Part l):441-477, 1985 Friederici HHR, Sebastian M: An argument for the attendance of clinicians at autopsy. Arch Pathol Lab Med 108:522-523, 1984 Roberts WC: The autopsy: its decline and a suggestion for its revival. N E n g l J M e d 299:332338, 1978 Collins JA: The importance of autopsies in geriat ric medicine. Geriatrics 36:33; 36; 38-39, October 1981 Goldman L: Autopsy: seventy-five years after Cabot (editorial). J Am Geriatr Soc 34:897-898, 1986 OrsiniLA: Health insurance and the autopsy. Am J Clin Pathol 69 (Suppl):248-249, 1978